AstraZeneca Pharma India Limited (NSE: ASTRAZEN) inaugurated its new corporate office in Mumbai, marking a significant step in its growth through innovation. The new office, spanning 25,600 sq ft, was inaugurated by Honorable Shri Devendra Fadnavis, Chief Minister of Maharashtra, alongside senior government officials and dignitaries.

Strategic Expansion

The new office signifies AstraZeneca’s ambition to transform care by unlocking the power of science. The company has introduced over 25 new medicines and indications in India in the past three years and is currently running about 80 global clinical trials in the country. This strategic move presents several opportunities for closer and effective partnerships with a vibrant healthcare ecosystem.

Commitment to Innovation

Arun Krishna, Non-Executive Director on the Board of AstraZeneca Pharma India Limited, emphasized India’s importance to AstraZeneca’s growth across Asia. The new commercial office in Mumbai will support closer engagement with stakeholders and the continued development of the company’s people. This step also supports AstraZeneca’s continued investment in talent and capability building in India, creating opportunities for professionals passionate about transforming healthcare.

As AstraZeneca expands, it will seek to attract and develop diverse talent across the value chain, reinforcing its broader purpose of advancing equitable healthcare globally. With this, India becomes one of the largest and diverse footprints of the organization around the world, supporting commercial operations, site management and monitoring, technology, research and development, and global business services.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

AstraZeneca drops 25.6% over three months and trades near its 52-week lows. The PEG reaches 3.73. The stock trades on brand and index weight, not on growth. Thin margins at 7.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Sellers drive 1.6x the volume of buyers. Furthermore, they controlled 18 of recent sessions versus 12 for buyers — a clear distribution signal. The business compounds at 31.3% revenue and 23.6% profit CAGR, with D/E of 0.00. Yet the stock drops 25.6% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of AstraZeneca Pharma India Limited.

AstraZeneca Pharma India Limited (ASTRAZEN) announced its financial results for the quarter ended June 30, 2026, reporting a 30% growth in total revenue from operations to INR 6,828 Mn in Q1 FY2026-27. The company’s performance was driven by continued momentum across its core therapy areas — Oncology, Biopharmaceuticals (CVRM and R&I) and Rare Disease, reflecting the strength of its innovation-led strategy, disciplined execution, and focus on improving patient outcomes in India.

Key Regulatory Approvals

During the quarter, the company strengthened its portfolio through key regulatory approvals, including:Acalabrutinib for Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), Mantle cell lymphoma (MCL), and HER2-positive breast cancer.

Strategic Initiatives

AstraZeneca Pharma India also advanced strategic initiatives, such as:Government of Telangana MoU for AI-enabled lung cancer screening, K+ Connect for hyperkalaemia management, and India Coronary Conquest 2026 for cardiovascular care.

Recognitions

The company received recognitions including the Medical Excellence Award for Rare Disease and Gold Award in Exceptional Employee Experience in Driving Business Impact.

Bhawana Agrawal, Chief Financial Officer & Director, said, ‘We delivered 30% growth in the first quarter, bringing our revenue to INR 6,828 Mn. This performance builds on our strong track record of delivering a consistent double-digit growth over the last five years. Our focus remains on investing strategically in opportunities that support sustainable long-term value creation.’ Mr. Praveen Rao Akkinepally, Country President & Managing Director, added, ‘Our purpose is to push the boundaries of science to deliver life-changing medicines, and this shapes how we serve unmet patient needs in India. The growth and momentum in the first quarter reflects the strength of our portfolio and focus on expanding access to serve more patients in India.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

AstraZeneca trades in the lower quarter of its 52-week range. The PEG stands at 4.55 — severely stretched. Any earnings miss could trigger a sharp de-rating. Thin margins at 8.2% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock sits at 23% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 31.3% and profits at 23.6%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of AstraZeneca Pharma India Limited.

AstraZeneca Pharma India Limited (the Company), a science-led biopharmaceutical company, today announced its full-year results for the financial year (FY) ended 31 March 2026. The Company maintained strong momentum during the year and delivered an impressive 33% year-on-year growth in total revenue, reflecting sustained performance across its therapy areas and continued progress in bringing innovative medicines to patients in India.

Financial Performance Summary

During FY 2025-26, AstraZeneca India recorded total revenue from operations of INR 22,755.8 Mn, supported by continued growth in Oncology and Biopharmaceuticals, as well as progress in Rare Disease. The year was also marked by 11 new regulatory approvals for medicines and indications, underscoring the Company’s commitment to scientific innovation, bringing them to the country at an accelerated pace and its focus on addressing unmet patient needs across India.

Key Highlights

Several important regulatory and business milestones were achieved during FY ’25-26, strengthening the Company’s portfolio and expanding patient access to innovative therapies in India. Notable approvals included Durvalumab for endometrial cancer, muscle invasive bladder cancer, and gastric cancer, among others. Additionally, Eculizumab was launched for the treatment of rare diseases, marking a significant milestone in this area.

Bhawana Agrawal, Chief Financial Officer & Director of the Company, said: “FY 2025-26 was a year of strong and consistent growth for AstraZeneca India, underpinned by the resilience of our business, the strength of our science-led portfolio, and disciplined execution across the organisation. Our performance reflects not only commercial momentum, but also our continued commitment to creating sustainable value through innovation, responsible growth, and meaningful impact for patients, society, and the planet.”

Praveen Rao Akkinepally, Managing Director, AstraZeneca India, added: “At AstraZeneca, science is at the heart of everything we do. Our FY 2025-26 performance reflects the progress we are making, accelerating the delivery of innovative medicines across key therapy areas and advancing our ambition to transform patient outcomes in India. With a strong pipeline and a clear sense of purpose, we remain focused on addressing unmet medical needs, advancing the healthcare ecosystem, and creating long-term impact through science-led innovation.”

Looking ahead, AstraZeneca Pharma India Limited remains committed to its mission of delivering great medicines to patients through innovative science and global excellence in development and commercialization.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

AstraZeneca moves sideways over three months, with neither buyers nor sellers taking control. The PEG stands at 4.78 — severely stretched. Any earnings miss could trigger a sharp de-rating. Thin margins at 9.2% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock holds at 45% of its 52-week range with RSI at 66. In other words, neither side has a clear edge right now. The business grows revenue at 28.6% and profits at 23.4%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 4.78 premium is usually justified. Check Fundamentals of AstraZeneca Pharma India Limited.